The omisirge market research report is one of a series of new reports that provides omisirge market statistics, including omisirge industry global market size, regional shares, competitors with an omisirge market share, detailed omisirge market segments, market trends and opportunities, and any further data you may need to thrive in the omisirge industry. This omisirge market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing healthcare expenditure, rising government initiatives, rising disposable income, increasing personalized medicines, and growing prevalence of cancer. Major trends in the forecast period include a focus on product launch, strategic collaboration, technological advancement, drug approval by authority, and investment in research and development.
The rising prevalence of cancer is anticipated to drive the growth of the omisirge market. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can invade adjacent tissues and metastasize to distant body parts, leading to severe health complications if untreated. This increase in cancer cases is attributed to various factors, including heightened exposure to carcinogens such as tobacco smoke, UV radiation, and certain chemicals, alongside an aging population, lifestyle changes, and genetic predispositions. Omisirge offers innovative treatment by enhancing the immune system’s ability to combat cancer cells, making it particularly effective for cancers resistant to conventional therapies. For instance, the American Cancer Society reported in January 2023 that cancer cases rose to 1,958,310, marking a 3.16% increase from 1,898,160 in 2021. This growing prevalence underscores the expansion of the omisirge market.
The demand for personalized treatments is expected to further fuel the growth of the omisirge market. Personalized treatments involve tailoring medical interventions to an individual’s genetic, environmental, and lifestyle factors to maximize therapeutic effectiveness and minimize side effects. Advances in genetic research, heightened awareness of personalized healthcare, and the superior efficacy of tailored therapies compared to traditional approaches are driving this demand. Omisirge supports personalized treatments by adapting to patient-specific needs, optimizing immune response targeting, and enhancing therapeutic outcomes based on each patient’s unique cancer profile. For example, the Personalized Medicine Coalition noted in February 2023 that personalized medicine accounted for 34% of FDA drug approvals in 2022 and has consistently represented at least 25% of annual approvals over the preceding eight years, highlighting its growing influence on the healthcare market.
Regulatory approvals are a significant trend driving innovation within the omisirge market. Drug approval processes involve regulatory authorities assessing new drugs to ensure their safety, efficacy, and quality, which are prerequisites for market entry. For example, in April 2023, Gamida Cell Ltd. received FDA approval for Omisirge for treating adult and pediatric patients aged 12 and older undergoing umbilical cord blood transplantation after myeloablative conditioning for hematologic malignancies. This development represents a breakthrough in cell therapy for blood cancer patients. Omisirge accelerates neutrophil recovery and reduces infection risks through a single intravenous dose derived from allogeneic stem cells cultured with nicotinamide. These stem cells are sourced from carefully selected unrelated donors, providing a robust therapeutic option for patients without relying on their own cells.
The key company operating in the omisirge market is Gamida Cell Ltd.
North America was the largest region in the omisirge market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in omisirge report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the omisirge market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Omisirge is a cutting-edge cell therapy employed in allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with blood cancers or disorders. Sourced from umbilical cord blood, it is specifically designed to accelerate neutrophil recovery, thereby minimizing the risk of infections and complications following transplantation. Omisirge includes expanded hematopoietic progenitor cells (CD34+ cells) that are cultured to increase their quantity and functionality, facilitating quicker engraftment compared to traditional cord blood transplantation.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Omisirge encompass conditions such as leukemia, lymphoma, myeloma, and others. Leukemia is a form of cancer affecting the blood and bone marrow, resulting in the overproduction of abnormal white blood cells. Omisirge is distributed via direct sales and through distributors, with its application spanning hospitals, clinics, and ambulatory surgical centers.
The omisirge market consists of sales of cell therapy products, gene therapy products, cord blood-derived products, and tissue engineering products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing healthcare expenditure, rising government initiatives, rising disposable income, increasing personalized medicines, and growing prevalence of cancer. Major trends in the forecast period include a focus on product launch, strategic collaboration, technological advancement, drug approval by authority, and investment in research and development.
The rising prevalence of cancer is anticipated to drive the growth of the omisirge market. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can invade adjacent tissues and metastasize to distant body parts, leading to severe health complications if untreated. This increase in cancer cases is attributed to various factors, including heightened exposure to carcinogens such as tobacco smoke, UV radiation, and certain chemicals, alongside an aging population, lifestyle changes, and genetic predispositions. Omisirge offers innovative treatment by enhancing the immune system’s ability to combat cancer cells, making it particularly effective for cancers resistant to conventional therapies. For instance, the American Cancer Society reported in January 2023 that cancer cases rose to 1,958,310, marking a 3.16% increase from 1,898,160 in 2021. This growing prevalence underscores the expansion of the omisirge market.
The demand for personalized treatments is expected to further fuel the growth of the omisirge market. Personalized treatments involve tailoring medical interventions to an individual’s genetic, environmental, and lifestyle factors to maximize therapeutic effectiveness and minimize side effects. Advances in genetic research, heightened awareness of personalized healthcare, and the superior efficacy of tailored therapies compared to traditional approaches are driving this demand. Omisirge supports personalized treatments by adapting to patient-specific needs, optimizing immune response targeting, and enhancing therapeutic outcomes based on each patient’s unique cancer profile. For example, the Personalized Medicine Coalition noted in February 2023 that personalized medicine accounted for 34% of FDA drug approvals in 2022 and has consistently represented at least 25% of annual approvals over the preceding eight years, highlighting its growing influence on the healthcare market.
Regulatory approvals are a significant trend driving innovation within the omisirge market. Drug approval processes involve regulatory authorities assessing new drugs to ensure their safety, efficacy, and quality, which are prerequisites for market entry. For example, in April 2023, Gamida Cell Ltd. received FDA approval for Omisirge for treating adult and pediatric patients aged 12 and older undergoing umbilical cord blood transplantation after myeloablative conditioning for hematologic malignancies. This development represents a breakthrough in cell therapy for blood cancer patients. Omisirge accelerates neutrophil recovery and reduces infection risks through a single intravenous dose derived from allogeneic stem cells cultured with nicotinamide. These stem cells are sourced from carefully selected unrelated donors, providing a robust therapeutic option for patients without relying on their own cells.
The key company operating in the omisirge market is Gamida Cell Ltd.
North America was the largest region in the omisirge market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in omisirge report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the omisirge market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Omisirge is a cutting-edge cell therapy employed in allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with blood cancers or disorders. Sourced from umbilical cord blood, it is specifically designed to accelerate neutrophil recovery, thereby minimizing the risk of infections and complications following transplantation. Omisirge includes expanded hematopoietic progenitor cells (CD34+ cells) that are cultured to increase their quantity and functionality, facilitating quicker engraftment compared to traditional cord blood transplantation.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Omisirge encompass conditions such as leukemia, lymphoma, myeloma, and others. Leukemia is a form of cancer affecting the blood and bone marrow, resulting in the overproduction of abnormal white blood cells. Omisirge is distributed via direct sales and through distributors, with its application spanning hospitals, clinics, and ambulatory surgical centers.
The omisirge market consists of sales of cell therapy products, gene therapy products, cord blood-derived products, and tissue engineering products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Omisirge Market Characteristics4. Omisirge Market Trends And Strategies5. Omisirge Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Omisirge Pricing Analysis & Forecasts30. Global Omisirge Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Omisirge Market32. Recent Developments In The Omisirge Market
3. Omisirge Market Biologic Drug Characteristics
6. Global Omisirge Growth Analysis And Strategic Analysis Framework
8. Omisirge Market Segmentation
9. Global Omisirge Epidemiology Of Clinical Indications
10. Omisirge Market Regional And Country Analysis
11. Asia-Pacific Omisirge Market
12. China Omisirge Market
13. India Omisirge Market
14. Japan Omisirge Market
15. Australia Omisirge Market
16. South Korea Omisirge Market
17. Western Europe Omisirge Market
18. UK Omisirge Market
19. Germany Omisirge Market
20. France Omisirge Market
21. Eastern Europe Omisirge Market
22. North America Omisirge Market
23. USA Omisirge Market
24. Canada Omisirge Market
25. South America Omisirge Market
26. Middle East Omisirge Market
27. Africa Omisirge Market
28. Omisirge Market Competitive Landscape And Company Profiles
29. Global Omisirge Market Pipeline Analysis
33. Omisirge Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Omisirge Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on omisirge market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for omisirge ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The omisirge market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Leukemia; Lymphoma; Myeloma; Other Hematologic Malignancies2) By Distribution Channel: Direct Sales; Distributors
3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers
Key Companies Profiled: Gamida Cell Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Gamida Cell Ltd.
